Literature DB >> 16879694

The leader sequence triggers and enhances several functions of clusterin and is instrumental in the progression of human prostate cancer in vivo and in vitro.

Qiang Zhang1, Wei Zhou, Shilajit Kundu, Thomas L Jang, Ximing Yang, Michael Pins, Norm Smith, Borko Jovanovic, Dianqi Xin, Lili Liang, Yinglu Guo, Chung Lee.   

Abstract

OBJECTIVE: To investigate the role of the leader sequence (which during clusterin biosynthesis facilitates its proper post-translational processing and secretion) in the functional activities of clusterin, a ubiquitous secretory glycoprotein with many biological functions, reported to be pro-apoptotic and anti-apoptotic in target cells, but for which the dual mechanism remains unclear.
MATERIALS AND METHODS: We designed an expression vector starting from the second in-frame ATG on the full-length human clusterin cDNA that was capable of driving the expression of both the full-length and the truncated isoforms of clusterin. We established stable expression clones of the androgen-dependent prostate cancer line LNCaP expressing clusterin with and without the leader sequence. This induced expression provided an opportunity to evaluate both the in vivo and in vitro actions of clusterin expression.
RESULTS: The LNCaP cells expressing clusterin with the leader sequence resisted apoptosis induced by tumour necrosis factor (TNF)-alpha, but clones with no leader sequence were highly susceptible to TNF-alpha-induced apoptosis. Furthermore, in the absence of the leader sequence, the expressed clusterin had a molecular weight consistent with that of the predicted holoprotein (40 kDa), suggesting a compromised post-translational processing with diffuse distribution throughout the cytoplasm. However, cells transfected with the full-length vector expressed clusterin of 60 and 35 kDa variants, and located exclusively in the Golgi apparatus. In vivo, only the overexpression of the full-length clusterin is anti-apoptotic and stimulates the proliferation of tumour.
CONCLUSION: The leader sequence is important in determining the functions of clusterin, which include anti-apoptotic and anti-necrotic properties. The lack of the leader sequence allowed the incompletely processed clusterin to induce apoptosis in target cells; without the leader sequence, clusterin functions differently. Thus, the leader sequence is a trigger for many functions of clusterin in the progression of human prostate cancer cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16879694     DOI: 10.1111/j.1464-410X.2006.06263.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  7 in total

1.  Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer.

Authors:  Amina Zoubeidi; Kim Chi; Martin Gleave
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

Review 2.  Clusterin: Review of research progress and looking ahead to direction in hepatocellular carcinoma.

Authors:  Peng Xiu; Xiao-Feng Dong; Xin-Ping Li; Jie Li
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

3.  Differential age-associated regulation of clusterin expression in prostate lobes of brown Norway rats.

Authors:  Josephat Omwancha; Matthew D Anway; Terry R Brown
Journal:  Prostate       Date:  2009-02-01       Impact factor: 4.104

Review 4.  Custirsen (OGX-011): clusterin inhibitor in metastatic prostate cancer.

Authors:  Sohaib Al-Asaaed; Eric Winquist
Journal:  Curr Oncol Rep       Date:  2013-04       Impact factor: 5.075

5.  Potential use of custirsen to treat prostate cancer.

Authors:  Celestia S Higano
Journal:  Onco Targets Ther       Date:  2013-06-25       Impact factor: 4.147

6.  Alzheimer's risk variants in the clusterin gene are associated with alternative splicing.

Authors:  M Szymanski; R Wang; S S Bassett; D Avramopoulos
Journal:  Transl Psychiatry       Date:  2011       Impact factor: 6.222

Review 7.  The use of long non-coding RNAs as prognostic biomarkers and therapeutic targets in prostate cancer.

Authors:  Cristian Arriaga-Canon; Inti Alberto De La Rosa-Velázquez; Rodrigo González-Barrios; Rogelio Montiel-Manríquez; Diego Oliva-Rico; Francisco Jiménez-Trejo; Carlo Cortés-González; Luis A Herrera
Journal:  Oncotarget       Date:  2018-04-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.